The clinical question remains as to whether stress is a trigger—or at least an exacerbating factor—in psoriasis and if so, how this should influence treatment approaches.
Combination treatment with methotrexate and narrowband ultraviolet light B provided marked improvement in patients with recalcitrant palmoplantar psoriasis.
Positive results were announced from a phase 3b study comparing bimekizumab (UCB) to secukinumab for the treatment of moderate to severe plaque psoriasis.
A 20% incremental dose regimen produces faster response in patients with psoriasis, without increasing the risk for adverse events in III-V skin types.
Wynzora is a combination of calcipotriene, a synthetic vitamin D3 analogue, and betamethasone dipropionate, a corticosteroid, which utilizes the Company’s proprietary PAD Technology platform enabling stability of both agents in an aqueous formulation.
Among patients with moderate to severe plaque psoriasis, treatment with mirikizumab (Lilly) was found to be noninferior to secukinumab (Cosentyx; Novartis).
A first clinical experience with brodalumab in an HIV-positive patient proves successful and may imply the utility of brodalumab in this patient group.
